Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Myeloproliferative Disorders × asciminib × Clear all

Phase

Phase 4 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Myeloproliferative Disorders 1 Bronchiolitis Obliterans Syndrome 1 Blast Crisis 1

Interventions

nilotinib 1 fludarabine phosphate 1 fludarabine 1 bosutinib 1 asciminib 1 Phlebotomy 1 Imatinib Mesylate 1 Dasatinib 1 Busulfan 1 Aspirin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04877522 2026-03-06

Asciminib Roll-over Study

Novartis

Phase 4 Recruiting

MyeloidOther hematologic neoplasm

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon ⚡